IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
IMUNON (Nasdaq: IMNN) hosted a public webcast on Nov 10, 2025 presenting translational and clinical data for its DNA-mediated immunotherapy IMNN-001.
Speakers included cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 MRD trials, clinicians, statistical experts and IMUNON executives. The event highlighted clinical findings that the company described as showing significant potential for women with advanced ovarian cancer.
A recording and symposium slides are available on IMUNON’s Scientific Presentations page at https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) ha ospitato un webcast pubblico il 10 novembre 2025 presentando dati traslazionali e clinici della sua immunoterapia mediata da DNA IMNN-001.
Tra i relatori vi erano importanti opinion leader nel campo oncologico, investigator principali dai trial Phase 3 OVATION 3 e Phase 2 MRD, medici, esperti statistici e dirigenti di IMUNON. L'evento ha evidenziato risultati clinici che l'azienda ha descritto come con potenziale significativo per le donne affette da cancro ovarico avanzato.
Una registrazione e le diapositive del simposio sono disponibili sulla pagina delle Presentazioni Scientifiche di IMUNON all'indirizzo https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) organizó una transmisión pública el 10 de noviembre de 2025 presentando datos translacionales y clínicos de su inmunoterapia mediada por ADN IMNN-001.
Entre los ponentes se encontraban líderes de opinión en cáncer, los investigadores principales de los ensayos Phase 3 OVATION 3 y Phase 2 MRD, clínicos, expertos en estadística y ejecutivos de IMUNON. El evento destacó hallazgos clínicos que la compañía describió como de potencial significativo para las mujeres con cáncer de ovario avanzado.
Una grabación y las diapositivas del simposio están disponibles en la página de Presentaciones Científicas de IMUNON en https://investors.imunon.com/scientific-presentations.
IMUNON (나스닥: IMNN)은 2025년 11월 10일에 공개 웹캐스트를 주최하여 DNA 매개 면역요법 IMNN-001의 번역적(translational) 및 임상 데이터를 발표했습니다.
연사는 암 분야의 주요 의견 리더, Phase 3 OVATION 3 및 Phase 2 MRD 연구의 주연 연구자, 임상의, 통계 전문가 및 IMUNON 경영진으로 구성되었습니다. 이 이벤트는 고급 단계의 난소암을 가진 여성에게 상당한 가능성을 보인다고 회사가 설명한 임상 발견을 강조했습니다.
녹음본과 심포지엄 슬라이드는 IMUNON의 과학 발표 페이지에서 https://investors.imunon.com/scientific-presentations에서 이용 가능합니다.
IMUNON (Nasdaq: IMNN) a organisé une webdiffusion publique le 10 novembre 2025 présentant des données translationnelles et cliniques pour son immunothérapie à ADN IMNN-001.
Les intervenants comprenaient des leaders d'opinion en oncologie, des chercheurs principaux issus des essais Phase 3 OVATION 3 et Phase 2 MRD, des cliniciens, des experts en statistiques et des dirigeants d'IMUNON. L'événement a mis en avant des résultats cliniques que la société a décrits comme présentant un potentiel significatif pour les femmes atteintes d'un cancer ovarien avancé.
Un enregistrement et les diapositives du symposium sont disponibles sur la page des Présentations Scientifiques d'IMUNON à l'adresse https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) veranstaltete am 10. November 2025 einen öffentlichen Webcast, in dem translations- und klinische Daten für die DNA- vermittelte Immuntherapie IMNN-001 vorgestellt wurden.
Zu den Referenten gehörten führende Krebs-Experten, Hauptprüfer aus den Studien Phase 3 OVATION 3 und Phase 2 MRD, Kliniker, Statistikexperten und IMUNON-Führungskräfte. Die Veranstaltung hob klinische Befunde hervor, die das Unternehmen als vielversprechend für Frauen mit fortgeschrittenem Ovarialkarzinom beschrieb.
Eine Aufzeichnung und die Vortragsfolien sind auf der Seite der Wissenschaftlichen Präsentationen von IMUNON unter https://investors.imunon.com/scientific-presentations verfügbar.
IMUNON (ناسداك: IMNN) عقدت بثًا حيًّا عامًا في 10 نوفمبر 2025 قدّمت البيانات النقلية والسريرية لعلاجها المناعي المعتمد على الحمض النووي IMNN-001.
شمل المتحدثون قادة رأي في السرطان، وباحثين رئيسيين من تجارب Phase 3 OVATION 3 وPhase 2 MRD، أطباء، خبراء إحصاء ونُوّاب IMUNON التنفيذيين. أشارت الفعالية إلى نتائج سريرية وصفتها الشركة بأنها تحمل إمكانات كبيرة للنساء المصابات بسرطان المبيض المتقدم.
يمكن الوصول إلى تسجيل الجلسة وشرائح الندوة على صفحة عروض IMUNON العلمية عند https://investors.imunon.com/scientific-presentations.
- None.
- None.
Webcast Recording and Symposium Slides Now Available
LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a compelling public webcast, where cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 minimal residual disease (MRD) trials, clinicians, statistical experts and IMUNON executives shared critical insights into the disease and translational data, along with compelling clinical data highlighting the significant potential of IMNN-001 for women with advanced ovarian cancer.
A webcast of the live event and presentation materials are available on the “Scientific Presentations” page of the IMUNON website at https://investors.imunon.com/scientific-presentations.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
Where can I watch IMUNON's Nov 10, 2025 webcast on IMNN-001 clinical data?
Which trials were discussed in the IMUNON Nov 10, 2025 webcast for IMNN (IMNN-001)?
Who spoke at IMUNON’s public webcast about IMNN-001 on Nov 10, 2025?
What clinical population was the focus of IMUNON’s Nov 10, 2025 presentation?
Does the Nov 10, 2025 IMUNON webcast include statistical and translational data for IMNN-001?
How can investors find the symposium slides from IMUNON’s Nov 10, 2025 event for IMNN?
